To Participate in Upcoming Investor Conferences

RNS Number : 0939G

Faron Pharmaceuticals Oy

23 November 2020

 

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron Pharmaceuticals to Participate in Upcoming Investor Conferences

TURKU - FINLAND, 23 November 2020   - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company , today announced that management will participate in the following virtual investor conferences:

· 32nd Annual Piper Sandler Virtual Healthcare Conference
Pre-recorded fireside chat available on-demand starting Monday, 23 November 2020 at 10:00 a.m. ET

· 3rd Annual Evercore ISI HealthCONx Conference

Fireside Chat on Wednesday, 2 December 2020 at 8:25 a.m. ET

Audio webcasts of the presentations will be available in the "Investors" section on Faron's website at https://www.faron.com/investors  

ENDS

For more information please contact:

Stern Investor Relations, Inc.

Julie Seidel, Naina Zaman

Phone: +(1)212 362 1200

Email: [e-mail]  

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: [phone]

E-mail: [e-mail]

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com  

 

END

 

 

NRAFESEFEESSEFF